À propos de MImAbs –

MImAbs is a CRO mastering the generation and characterization of antibodies/ADCs and aiming to accelerate novel therapeutics to the regulatory phase. With a team of multidisciplinary experts and strategic partnerships in place, we are uniquely positioned to drive innovation through all pre-clinical stages of your drug development journey.

With the incorporation of cutting-edge cell screening technology (Beacon® Optofluidic System), we have streamlined the labour-intensive antibody discovery process, enabling the identification of rare highly specific antibodies. MImAbs guarantees the generation of antibodies for the most challenging targets. Antibodies can then be engineered as Fc competent/silent naked antibodies or as ADCs.